Faculty

Back to Index
Michael N. Neely, MD
Associate Professor of Pediatrics (Clinical Scholar)
Pediatrics
CHLA 4650 W. Sunset Blvd. Off Campus Los Angeles
+1 323 361 5047

Overview

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently board certified in Pediatrics and Pediatric Infectious Diseases, and he is the co-Director of the Laboratory of Applied Pharmacokinetics in the University of Southern California (USC) Keck School of Medicine, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, and Preventive Medicine, in the Schools of Pharmacy and Mathematics, and the Jet Propulsion Laboratory in Pasadena, CA. With expertise in computerized drug-response modeling, he is applying his research interests to the care of his patients by operating the first HIV therapeutic drug management service at LAC+USC, which is available to all HIV providers. He also provides out- and inpatient pharmacologic consultation for a wide range of therapeutically challenging cases. In the fall of 2010, he will complete a Master’s of Science program in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he has recently been appointed to the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He has received NIH funding for most of his post-doctoral career, is the author of numerous papers and abstracts, and he is invited to give talks and workshops on dose individualization and optimization worldwide.

Publications

Mathew SK, Mathew BS, Neely MN, Naik GS, Prabha R, Jacob GG, K S, Fleming DH. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients. Ther Drug Monit. 2016 Oct; 38(5):593-9. View in: PubMed

Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. J Antimicrob Chemother. 2016 Aug; 71(8):2234-40. View in: PubMed

Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, Schumitzky A, Bleyzac N, Goutelle S. Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. Ther Drug Monit. 2016 Jun; 38(3):332-42. View in: PubMed

Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin Drug Metab Toxicol. 2016 May; 12(5):533-44. View in: PubMed

Huurneman LJ, Neely M, Veringa A, Docobo Pérez F, Ramos-Martin V, Tissing WJ, Alffenaar JW, Hope W. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2336-42. View in: PubMed

Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016 Feb; 22(2):78-83. View in: PubMed

Billat PA, Woillard JB, Essig M, Sauvage FL, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2016 Feb; 71(2):484-9. View in: PubMed

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrob Agents Chemother. 2015 Jun; 59(6):2986-94. View in: PubMed

Jelliffe RW, Schumitzky A, Bayard D, Fu X, Neely M. Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. Ther Drug Monit. 2015 Jun; 37(3):389-94. View in: PubMed

Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, Orbach R, Liu S, Louie S, Hope W. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015 Jun; 59(6):3090-7. View in: PubMed

Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study. Transplantation. 2015 Apr 16. View in: PubMed

Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL. Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia. J Infect Dis. 2015 Apr 15; 211(8):1326-33. View in: PubMed

Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother. 2015 Mar 22. View in: PubMed

Neely M, Louie S, Xu J, Anthony P, Thuvamontolrat K, Mordwinkin N, Kovacs A. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy. J Clin Pharmacol. 2015 Feb 12. View in: PubMed

Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother. 2015; 60(3):1401-10. View in: PubMed

Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014 Nov 20; 77:50-7. View in: PubMed

Neely M, Kaplan EL, Blumer JL, Faix DJ, Broderick MP. A Population Pharmacokinetic Modeling Approach Shows that Serum Penicillin G Concentrations Are Below Inhibitory Concentrations by Two Weeks after Benzathine Penicillin G Injection in the Majority of Young Adults. Antimicrob Agents Chemother. 2014 Nov; 58(11):6735-41. View in: PubMed

Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, Marquet P, Saint-Marcoux F. Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. Br J Clin Pharmacol. 2014 Oct; 78(4):836-46. View in: PubMed

Kinney ME, Lamberski N, Wack R, Foster R, Neely M, Tell L, Gehring R. Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii). J Vet Pharmacol Ther. 2014 Oct; 37(5):500-7. View in: PubMed

Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies DL. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport. 2014 Sep 10; 25(13):1018-23. View in: PubMed

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN. The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. Curr Pharm Des. 2014 Sep 1. View in: PubMed

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun; 14(6):498-509. View in: PubMed

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014 Jan; 58(1):309-16. View in: PubMed

Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One. 2014; 9(7):e101311. View in: PubMed

Atrio J, Stanczyk FZ, Neely M, Cherala G, Kovacs A, Mishell DR. Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women. J Acquir Immune Defic Syndr. 2014 Jan 1; 65(1):72-7. View in: PubMed

Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. Antimicrob Agents Chemother. 2013 Dec; 57(12):5854-9. View in: PubMed

Tatarinova T, Kryshchenko A, Triska M, Hassan M, Murphy D, Neely M, Schumitzky A. NPEST: a nonparametric method and a database for transcription start site prediction. Quant Biol. 2013 Dec; 1(4):261-271. View in: PubMed

Asberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013 Nov; 26(12):1198-207. View in: PubMed

Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A, Wiegand R, Wheeling T, Bohannon B, Dominguez K. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013 Sep; 32(9):e370-6. View in: PubMed

O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013 Jul 15; 208(2):351-61. View in: PubMed

Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, Neely MN. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013 Apr; 57(4):1888-94. View in: PubMed

Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013 Apr; 40(2):189-99. View in: PubMed

Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, Kiss A, Neely M. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb; 115(2):224-32. View in: PubMed

Schaudinn C, Gorur A, Webster P, Jones AC, Neely M, Jelliffe RW, Le AD, Sedghizadeh PP. Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct; 114(4):480-6. View in: PubMed

Montoya JG, Neely MN, Gupta S, Lunn MR, Loomis KS, Pritchett JC, Polsky B, Medveczky PG. Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. J Clin Virol. 2012 Sep; 55(1):40-5. View in: PubMed

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012 Aug; 34(4):467-76. View in: PubMed

Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother. 2012 Jun; 56(6):2959-66. View in: PubMed

Rakhmanina NY, Neely MN, Capparelli EV. High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. Ther Drug Monit. 2012 Jun; 34(3):237-41. View in: PubMed

Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012 May; 18(5):731-8. View in: PubMed

Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012 May; 129(5):e1343-7. View in: PubMed

Charhon N, Neely MN, Bourguignon L, Maire P, Jelliffe RW, Goutelle S. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob Agents Chemother. 2012 Apr; 56(4):1862-9. View in: PubMed

Neely M, Louie S. Obesity and its impact on drug therapy: are we ready for this change? Clin Pharmacokinet. 2011 Dec 1; 50(12):825-6. View in: PubMed

Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol. 2011 Dec; 12(12):2044-61. View in: PubMed

Schein R, Homans J, Larsen RA, Neely M. Posaconazole for chronic refractory coccidioidal meningitis. Clin Infect Dis. 2011 Dec; 53(12):1252-4. View in: PubMed

Jelliffe R, Neely M, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Bustad A, Laing D, Yamada W, Bartroff J, Tatarinova T. Nonparametric population modeling and Bayesian analysis. Pharmacol Res. 2011 Oct; 64(4):426. View in: PubMed

Goutelle S, Neely M, Bleyzac N. Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011 Sep; 45(9):1171-2. View in: PubMed

Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011 Aug; 33(4):417-24. View in: PubMed

Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, McSherry GD, Spector SA, Gaur AH. Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health. 2011 Jun; 48(6):637-40. View in: PubMed

Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. 2011 May; 12(5):531-8. View in: PubMed

Neely MN, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet. 2011 Mar 1; 50(3):143-89. View in: PubMed

Festekjian A, Neely M. Incidence and predictors of invasive candidiasis associated with candidaemia in children. Mycoses. 2011 Mar; 54(2):146-53. View in: PubMed

Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, Calmy A. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010 Nov; 54(11):4619-25. View in: PubMed

Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, McSherry G, Spector SA, Flynn PM. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses. 2010 Sep; 26(9):947-53. View in: PubMed

Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol. 2010 Jul; 50(7):842-7. View in: PubMed

Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010 Jun; 32(3):273-81. View in: PubMed

Neely MN, Rakhmanina NY. Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother. 2010 Apr; 65(4):808-9; author reply 809-10. View in: PubMed

Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010 Jan 1; 50(1):27-36. View in: PubMed

Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag. 2009 Jun; 5(3):595-615. View in: PubMed

Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009 Jun; 53(6):2532-8. View in: PubMed

Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009 Apr; 53(4):1450-6. View in: PubMed

Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008 Sep; 48(9):1081-91. View in: PubMed

Neely MN, Benning L, Xu J, Strickler HD, Greenblatt RM, Minkoff H, Young M, Bremer J, Levine AM, Kovacs A. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Jan 1; 44(1):38-42. View in: PubMed

Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov; 49(11):4536-45. View in: PubMed

Neely M, Kovacs A. Management of antiretroviral therapy in neonates, children, and adolescents. Curr HIV/AIDS Rep. 2004 Jun; 1(2):97-104. View in: PubMed

Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003 Aug; 3(2):61-7. View in: PubMed

Neely M, Blumer J. Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients. Curr Ther Res Clin Exp. 2003 Feb; 64(2):127-36. View in: PubMed

Powered bySC CTSI